News on CRISPR, gene editing, RNAi in genetics, genomics, and molecular diagnostics.
The deal is part of a wider collaboration between the companies to develop molecular diagnostic tests using their respective platforms.
The company is in talks with potential partners in the US and China to validate the assay on clinical samples and deploy it at a large scale.
The company recently inked deals with Mammoth Biosciences and Rutgers University to license a protein discovery platform and gene editing technology.
Vienna-based Aelian combines CRISPR-Cas9 screening techniques with single-cell sequencing to identify and investigate disease targets and drug mechanisms of action.
The EPO rejected arguments that were filed in opposition to the patent, which covers the use of CRISPR-Cas9 in cellular and non-cellular settings.
According to NPR, an antibody-based test could identify people who were exposed to SARS-CoV-2 and either didn't develop symptoms or were misdiagnosed.
A sequencing analysis of New York City rats indicates they have adapted to the urban environment there, according to a recent preprint.
Ars Technica reports that a multicellular eukaryotic parasite has lost its mitochondria.
In Science this week: perspective piece says AI can accelerate drug discovery by using genomic and chemical data, and more.
